Wanbury's Q1 Profit Soars to ₹135 Crore, Revenue Climbs to ₹1.6 Billion

Wanbury Limited , a prominent player in the pharmaceutical sector, has reported a remarkable financial performance for the first quarter. The company's consolidated net profit surged to ₹135.00 crore, marking a significant increase from ₹10.40 crore in the same period last year.

Revenue Growth

The company's revenue showed robust growth, reaching ₹1.60 billion compared to ₹1.30 billion in the corresponding quarter of the previous year. This represents a year-over-year increase of approximately 23%.

Improved Profitability

Wanbury's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) more than doubled, rising to ₹244.00 crore from ₹110.00 crore in the same quarter last year. This substantial increase in EBITDA reflects the company's improved operational efficiency and cost management.

Margin Expansion

The EBITDA margin saw a significant expansion, reaching 14.98% compared to 8.37% in the previous year. This margin improvement of over 660 basis points indicates the company's ability to enhance its profitability while growing its revenue.

Financial Position

According to the unaudited standalone financial results:

Particulars (₹ in Lakhs)	Q1 FY2026	Q1 FY2025	YoY Change
Revenue from operations	16,318.40	13,110.82	24.47%
Total Income	16,353.14	13,205.28	23.84%
Profit before tax	1,360.58	103.74	1211.52%
Profit after tax	1,349.05	103.74	1200.41%

The standalone results show a substantial improvement in profitability, with profit after tax increasing by over 1200% year-over-year.

Conclusion

Wanbury Limited's first-quarter performance demonstrates strong growth across key financial metrics. The substantial increase in net profit, coupled with robust revenue growth and margin expansion, positions the company favorably. Investors and stakeholders will likely be watching closely to see if this momentum can be sustained in the coming quarters.

Note: All figures are based on the consolidated results unless otherwise specified.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.87%	-8.62%	-2.35%	-7.49%	-3.88%	+595.99%

Wanbury Limited , a prominent player in the pharmaceutical sector, has announced its unaudited financial results for the first quarter, along with several key corporate decisions.

Robust Financial Performance

The company reported significant year-on-year growth in its financial metrics for Q1:

Revenue from operations stood at ₹16,318.40 lakhs, compared to ₹13,110.82 lakhs in the same quarter last year, marking a 24.5% increase.
Profit after tax surged to ₹1,349.05 lakhs, a substantial rise from ₹103.74 lakhs in Q1 of the previous year.
The company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) also showed improvement, indicating enhanced operational efficiency.

Particulars (in Lakhs)	Q1 Current	Q1 Previous	YoY Growth
Revenue from Operations	16,318.40	13,110.82	24.5%
Profit After Tax	1,349.05	103.74	1200.0%

Employee Stock Option Plan (ESOP) Grant

In a move to align employee interests with company growth, Wanbury's Board of Directors approved the grant of 91,500 stock options under the Wanbury ESOP 2016 scheme. Key details of the grant include:

Options will vest over two years, with 40% allocated for loyalty and 60% for performance.
The exercise price is set at ₹10 per option.
This decision aims to enhance employee motivation and retention.

Leadership Continuity

The Board has recommended the reappointment of Mr. Chandran Krishnamoorthy as Whole-time Director for another five-year term, effective from September 18, 2025. This decision, subject to shareholder approval, underscores the company's commitment to stable leadership and strategic continuity.

Streamlining Operations

In a strategic move, Wanbury has initiated the closure of three foreign subsidiaries located in the Netherlands, China, and UAE. These subsidiaries had not commenced any business operations since their incorporation. The company assures that this decision will not impact its revenue or business operations.

Market Response

The financial results and corporate actions have been well-received by the market. The company's strong performance, especially in revenue growth and profitability, reflects its resilience and effective business strategies in the competitive pharmaceutical landscape.

Wanbury Limited continues to focus on operational excellence and strategic expansion in the pharmaceutical sector. With its robust financial performance and forward-looking corporate decisions, the company appears well-positioned for sustained growth in the coming quarters.

Note: All financial figures are based on standalone results unless otherwise specified.